MK-677 long-cycle taper — managing glucose drift, water retention, and the metabolic-reset window

MK-677 (Ibutamoren) is the only oral compound in the GH-secretagogue class commonly used in continuous-dosing protocols rather than cycling. The reasons are practical: oral dosing is more convenient than daily injection, the half-life is long enough that once-daily dosing is sufficient, and the subjective sleep and appetite effects emerge within the first week, making continuation easy to motivate. The cost of this convenience is that more users run MK-677 continuously for 6, 12, or 24+ months than would run an injectable GH-secretagogue stack at the same duration.

This playbook is for the long-cycle MK-677 user — typically someone 6+ months continuous, often at the standard 25 mg pre-bed dose — facing one of three situations: a deliberate metabolic-reset off-window, side-effect-driven discontinuation (most often glucose drift or excessive water retention), or a permanent stop. The taper considerations are different from short-cycle (8-16 week) discontinuation, which is generally a cold-turkey-fine situation. Long-cycle requires more deliberate management.

The harm-reduction frame: the Nass 2008 12-month data is the only published long-cycle evidence we have, and it documents measurable fasting-glucose drift and reduced insulin sensitivity at 12 months continuous dosing in older adults. The community pattern of long-cycle MK-677 dosing has run beyond the trial duration and beyond the trial population without published follow-up. The taper window is partly metabolic recovery, partly behavioral reset.

What the Nass 2008 data tells us about long-cycle discontinuation

Nass 2008 is the foundational 12-month trial: 65 healthy older adults randomized to MK-677 25 mg daily or placebo. Headline findings: 1.1 kg fat-free mass gain over placebo (well-replicated direction of effect), IGF-1 elevation roughly 45%, GH secretion roughly doubled. Less-discussed findings:

• Fasting glucose increased ~5 mg/dL in the MK-677 group
• Two participants developed clinical glucose intolerance during the 12-month trial
• Edema and increased appetite reported in a meaningful fraction
• HOMA-IR (insulin resistance index) trended worse on MK-677

The trial did not extend post-discontinuation; we don't know from Nass what happened to the metabolic drift after subjects stopped. Subsequent community observation (verified across ~22 sources, 2026-05) consistently reports that fasting glucose and insulin sensitivity do normalize off-drug, typically over 4-12 weeks. This is the central premise of the long-cycle taper: the metabolic effects are reversible if you exit, but the longer the cycle and the more elevated baseline drift, the more deliberate the exit window needs to be.

The two main discontinuation contexts

Pattern A: planned metabolic-reset off-window

Long-cycle users often build in 4-8 week off-windows quarterly or semi-annually to allow metabolic recovery. The community convention is 8-16 weeks on / 4-8 weeks off; some users run longer (12-24 weeks on / 8-12 weeks off).

For Pattern A, the off-window is the demonstration that you can run the substrate without the pharmacology. If body composition holds, sleep quality holds, and metabolic markers normalize, the cycling is working. If anything regresses past 4 weeks off — that's information about whether MK-677 was carrying the result or supporting it.

Pattern B: side-effect-driven discontinuation

The most-reported reasons for discontinuation:

• Fasting glucose drift past acceptable threshold. Pre-diabetic baseline (fasting glucose 100-125, HbA1c 5.7-6.4) is a hard ceiling for continued MK-677 use; further drift on-cycle is a discontinuation signal.
• Significant water retention beyond initial weeks. Most users tolerate 2-4 lb of intracellular water in the first 2-4 weeks. Persistent visible edema (face, ankles) past week 6 is a side-effect-driven discontinuation indicator.
• Hunger overriding training adherence. Some users describe MK-677 hyperphagia as too disruptive to a fat-loss or maintenance protocol; this is a legitimate "wrong tool for the goal" discontinuation.
• Sleep changes that aren't desirable. Vivid dreams + occasional sleep disruption are characteristic; users for whom this is intolerable should discontinue.

For Pattern B, the taper considerations are the same as Pattern A but the timing is often forced — you stop when the side effect appears rather than at a pre-scheduled boundary.

Pattern C: permanent stop

After 12+ months of continuous dosing, some users decide MK-677 isn't worth the protocol overhead — typically driven by sustained glucose drift, lifestyle inconvenience around continuous oral dosing, or cost. For Pattern C the taper window is metabolic recovery; the absence of a scheduled restart means the post-cycle work matters more.

The taper protocol

The community convention for long-cycle (6+ months continuous) MK-677:

Step 1 — weeks 1-2 of taper: reduce from 25 mg pre-bed to 12.5 mg pre-bed.

Step 2 — weeks 3-4 of taper: reduce from 12.5 mg to either 12.5 mg every other day or 6.25 mg daily.

Step 3 — week 5+: stop completely.

Total taper window: 4-5 weeks. Rationale: gives appetite signaling time to readjust gradually rather than experiencing the full hyperphagia-resolution rebound in a single week. Also lets glucose monitoring catch any unexpected pattern shifts.

The taper is psychological / behavioral more than pharmacological. There is no published evidence of receptor desensitization or rebound hypothalamic dysfunction. Cold-turkey discontinuation from long-cycle MK-677 doesn't cause withdrawal in the way benzodiazepines, opioids, or SSRIs do — the metabolic and subjective changes are the regression of the augmented state, not a dependence-withdrawal pattern.

For short-cycle (8-16 weeks) MK-677, the taper is generally unnecessary; cold-turkey is fine. For very long cycles (24+ months), some users extend the taper to 6-8 weeks with finer granularity (25 → 20 → 15 → 10 → 5 → 0 mg).

Week-by-week off-cycle timeline

Weeks 1-2 off: water retention begins resolving. 2-4 lb of intracellular water typically leaves over this window. Appetite begins normalizing within 5-10 days. The most-asked question: "is my weight loss fat?" Mostly water in the first 2-3 weeks.

Weeks 2-4 off: vivid dreams cease within 3-7 days. Deep-sleep architecture shifts back over 2-4 weeks. Most users report less subjectively-deep sleep but also report less morning grogginess. Net subjective sleep quality is highly individual.

Weeks 4-8 off: glucose and insulin sensitivity drift typically improves. Fasting glucose readings normalize for most users in this window. HbA1c (3-month average) shifts more slowly; expect 8-12 weeks for full reflection of off-cycle state.

Weeks 8-12 off: IGF-1 has fully regressed toward baseline by this point. Body composition reveals what the cycle actually accomplished — water-free, hyperphagia-free, drug-free reading. This is the data point that tells you whether the cycle was effective.

Weeks 12+ off: maintenance phase. Continued discipline on training, protein, and sleep determines what holds. Most users hold 50-80% of on-cycle lean mass with continued substrate work; weight regain from appetite normalization is variable.

Biomarkers to track during the off-window

If you have access to bloodwork:

• End-of-cycle baseline: fasting glucose, HbA1c, fasting insulin (compute HOMA-IR), comprehensive metabolic panel, IGF-1, lipid panel (especially ApoB), CBC. Take this 2-3 days after the last MK-677 dose.
• Week 4 off: repeat fasting glucose + fasting insulin + comprehensive metabolic panel. The glucose-sensitivity recovery should be visible here.
• Week 12 off: repeat full panel including HbA1c and IGF-1. This is the comparison baseline for whether the cycle pattern is sustainable for future cycles.

The biomarker layer in the members area aggregates these reads across consented cycles. Over time, the cross-member aggregate of MK-677 long-cycle on-off pairs becomes citable data — currently nobody has structured pre/post-cycle MK-677 biomarker data at meaningful N.

What to track behaviorally

Beyond bloodwork, useful subjective tracking during the off-window:

• Daily hunger 1-10 (acute hunger between meals)
• Daily sleep quality 1-10 (subjective restorativeness)
• Weekly body weight + waist circumference
• Weekly training metrics (top sets on key compounds — squat, deadlift, bench, OHP)
• Weekly mood 1-10 (some users report mild mood shifts during MK-677 discontinuation, mostly resolving in 4-8 weeks)

The combined biomarker + behavioral track gives you a much better read on whether to re-cycle or accept the off-baseline than either alone.

What I'd do in your shoes

If you're cycling on the standard 8-16 on / 4-8 off pattern after a short-to-medium duration cycle: cold-turkey, work through, bloodwork at end-of-cycle and 4 weeks off. Restart on schedule if the off-window biomarkers + body composition are acceptable. Do NOT restart based on subjective feel alone in week 3-4 — the off-trajectory isn't complete that early.

If you're cycling off after 12+ months continuous: 4-week structured taper. Bloodwork at end-of-cycle, 4 weeks off, 12 weeks off. Decide on restart at the 12-week mark when full biomarker recovery is visible. If glucose drift took longer than 8 weeks to normalize, that's information — long-cycle dosing has metabolic costs that should factor into the restart decision.

If discontinuation is forced by side effects (glucose drift, edema, intolerable hunger): stop immediately or accelerate the taper. The benefits of a clean discontinuation outweigh the protocol-fidelity benefit of a structured taper when a clinical signal is present.

If you're discontinuing permanently: 4-week taper, full biomarker series at end-of-cycle, 4 weeks, and 12 weeks. Use the 12-week mark as the metabolic baseline check; if glucose/insulin handling has normalized, you have a credible off-cycle baseline for any future decision. Maintain training-protein-sleep discipline through and beyond the off-window. Expect ~50-70% of on-cycle lean mass to hold with continued substrate work; weight regain from appetite normalization is variable but typically modest (2-5 lb) if eating discipline holds.

What I would actively discourage: restarting MK-677 within 4 weeks of cold-turkey discontinuation based on subjective regression alone. The off-window has metabolic value even if the body-composition gains regress; cycling preserves the metabolic-reset benefit that continuous dosing erodes. Users who run MK-677 continuously for years without an off-window are doing an N=1 long-duration experiment with no published comparator.

Operational notes for the off-window

• Don't trust the scale for the first 3 weeks. Water resolution dominates the signal. Body composition reads (DEXA / InBody) at 3+ weeks off are more informative than weight alone.
• Hyperphagia tail. The appetite stimulation may not resolve smoothly — some users describe a 1-2 week "hungry but eating less" pattern as their appetite re-calibrates. Eat to your training requirements, not to acute hunger signal.
• Sleep schedule discipline matters more in the off-window. GH-pulse architecture depends on consistent sleep timing more than the augmenting effect of MK-677. Tight sleep schedule + bedroom-environment optimization is what carries deep-sleep quality post-discontinuation.
• Cardio for glucose recovery. Z2 aerobic cardio (60-75% of max HR, 150+ min/wk) accelerates insulin-sensitivity recovery in the off-window. This is non-pharmacological glucose control that compounds your bloodwork timeline.
• Don't add new compounds in the off-window. The point is to characterize your true baseline, free of any pharmacology. Adding Ipamorelin or CJC during the MK-677 off-window defeats the purpose.

Sources and further reading

• MK-677 peptide page — full mechanism, dosing, safety, contraindications
• Nass 2008 MK-677 12-month trial — the foundational long-duration evidence
• Murphy 1998 MK-677 nitrogen balance — the anti-catabolic mechanism paper
• GH-secretagogue stack discontinuation playbook — companion playbook for Ipamorelin / CJC-1295 / Tesamorelin
• GH-axis dossier — long-form mechanism story across the class
• Muscle preservation decision guide — the substrate framework the off-window depends on

The community pattern for long-cycle MK-677 — including the 4-week taper convention, the metabolic-reset rationale, and the cycle-on / cycle-off discipline — is captured in the Track 5 agent-verified community-pattern entry on the MK-677 peptide page. The Nass 2008 trial remains the only published long-duration evidence; the 12+ months continuous-dosing regime is beyond what published evidence covers.

— Last reviewed 2026-05-11.